IO Biotech, Inc.

NASDAQ:IOBT

2.19 (USD) • At close July 29, 2025
Bedrijfsnaam IO Biotech, Inc.
Symbool IOBT
Munteenheid USD
Prijs 2.19
Beurswaarde 144,279,193
Dividendpercentage 0%
52-weken bereik 0.66 - 2.477
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mai-Britt Zocca Ph.D.
Website https://www.iobiotech.com

An error occurred while fetching data.

Over IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as

Vergelijkbare Aandelen

Assertio Holdings, Inc. logo

Assertio Holdings, Inc.

ASRT

0.711 USD

Ikena Oncology, Inc. logo

Ikena Oncology, Inc.

IKNA

17.16 USD

DarioHealth Corp. logo

DarioHealth Corp.

DRIO

0.545 USD

AVITA Medical, Inc. logo

AVITA Medical, Inc.

RCEL

9.96 USD

Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

SLGL

12 USD

Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc.

CTXR

1.47 USD

Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

OVID

0.54 USD

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH

0.35 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)